Apitolisib helps overcome resistance to traditionaltherapies and enhances the efficacy of other cancer treatments (Figure ). Similarly, GNE-477 is a potent dual PI3K/mTOR inhibitorwith promising anticancer activity and has shown efficacy in preclinicalmodels, making it a potential candidate for cancer therapy. Compound I is an amino-thienopyrimidineanalog, a potent EGFR inhibitor developed from bioisosteric replacementof the pyrrolopyrimidine lead compound, while thienyl-substituted thienopyrimidine II was foundto be an excellent inhibitor for FLT3. Here, EGFR is linked to cancer.